.Attribute Medicine, Released online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized phase 3b/4 DESTINY-Breast12 study, trastuzumab deruxtecan (T-DXd) treatment of individuals with HER2+ enhanced breast cancer cells and energetic or even dependable mind metastases presented constant intracranial activity as well as systemic efficacy of T-DXd.